Arvinas Q3 revenue drops sharply on lower milestone payments
ARVN•Arvinas reported Q3 2026 revenue of $500,000, citing the absence of milestone and collaboration payments recognized a year earlier, and a net loss of $53.9 million. It expects its cash reserves to fund operations into the second half of 2028.
1. Quarterly results
Arvinas reported Q3 2026 revenue of $500,000, attributing the decline to the absence of milestone and collaboration payments recognized in the prior year. The company posted a net loss of $53.9 million and operating expenses of $59.6 million.
2. Costs and cash outlook
Operating expenses declined, mainly because of lower research and development and general and administrative costs. Lower research and development spending reflected reduced spending on the vepdegestrant (ARV-471) program and lower personnel costs. Arvinas expects its cash reserves to fund operations into the second half of 2028.
